BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.45, Yahoo Finance reports.
BriaCell Therapeutics Price Performance
BCTX opened at $0.82 on Wednesday. The business has a 50 day moving average price of $0.80 and a two-hundred day moving average price of $1.15. The company has a market capitalization of $14.90 million, a price-to-earnings ratio of -0.67 and a beta of 1.34. BriaCell Therapeutics has a 1-year low of $0.46 and a 1-year high of $5.97.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of BriaCell Therapeutics in a research note on Thursday, October 3rd.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- Top Stocks Investing in 5G Technology
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
- 3 Monster Growth Stocks to Buy Now
- 3 ETFs With Low Fees and Market-Beating Returns
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
